- March 09, 2012
- Taiho Pharmaceutical Co., Ltd.
Licensing Agreement Cancelled for NST-141 Agent for Pruritus in Atopic Dermatitis
Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Toru Usami) announced today that the licensing agreement with Nippon Shinyaku Co., Ltd. (HQ: Kyoto, President: Shigenobu Maekawa) for the new NST-141 agent for pruritus in atopic dermatitis has been cancelled by mutual consent.
Discovered by Nippon Shinyaku Co., Ltd., NST-141 is a new antipruritic agent for external administration. The said agreement covering joint development and collaborative marketing in Japan had been concluded on October 1, 2008.
Information in this news release was current as of the original release date.